BiotechTube
Fore Biotherapeutics

Fore Biotherapeutics

Philadelphia, United States· Est.
fore.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $49.2M

Overview

Fore Biotherapeutics is a private, pre-revenue biotech advancing a targeted oncology pipeline, anchored by its lead asset plixorafenib. The company is currently conducting a Phase 2 basket trial (FORTE) to evaluate plixorafenib's efficacy and safety in advanced solid tumors with various BRAF alterations, having recently reported positive interim data. Operating with a virtual model, Fore is backed by top-tier investors and focuses on in-licensing clinic-ready compounds to rapidly deliver therapies to patients with limited treatment options.

Oncology

Technology Platform

Focus on in-licensing clinic-ready precision oncology compounds; lead asset is a next-generation BRAF inhibitor designed for broad-spectrum activity against V600 and non-V600 mutations, fusions, and splice variants.

Funding History

100
Total raised:$49.2M
Grant$116K
Grant$280K
Grant$500K
Grant$426K

Opportunities

Plixorafenib addresses a large unmet need in non-V600 BRAF mutant cancers, which lack approved targeted therapies, representing a new market segment.
Its potential as a well-tolerated monotherapy could also capture market share in later-line V600-mutant cancers post-progression on standard combo therapy.
Positive clinical data could attract partnership or acquisition interest from larger oncology companies.

Risk Factors

High clinical risk as the Phase 2 trial may not yield data sufficient for approval or competitiveness.
The company's virtual model and single-asset pipeline create operational and concentration risk.
As a private, pre-revenue firm, it is dependent on successful future fundraising, which is subject to market conditions and clinical results.

Competitive Landscape

Fore competes in the crowded BRAF/MEK inhibitor market dominated by Roche/Genentech (vemurafenib/cobimetinib) and Novartis (dabrafenib/trametinib). It also faces competition from other next-generation BRAF and pan-RAF inhibitors in development from companies like Pfizer, Kinnate Biopharma, and others, all aiming to overcome resistance and target non-canonical mutations.

More companies in Small Molecule Drugs →More companies in United States →